The effect of moxonidine on endothelial dysfunction in metabolic syndrome
Küçük Resim Yok
Tarih
2006
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background: Endothelial dysfunction has been reported in patients with type 2 diabetes mellitus and even in healthy obese individuals with a normal metabolic profile. Sympathetic activity commonly is increased in obese hypertensive patients, and moxonidine is effective in lowering BP and improving insulin sensitivity. Objective: To evaluate the effect of moxonidine on endothelial dysfunction in patients with metabolic syndrome. Methods: Twenty-six patients with mild hypertension were treated with moxonidine and a hypocaloric diet for 3 months, while a second normotensive group (n = 26) were followed-up with calorie restriction alone. Anthropometric (body mass index, waist and hip circumferences, and waist-to-hip ratio) and metabolic features (fasting plasma glucose and insulin, aminotransferases, ?-glutamyl transpeptidase, triglycerides, and cholesterol levels) and flow-mediated dilatation (FMD) were evaluated. Insulin resistance was calculated by using the homeostasis model assessment formula. Insulin sensitivity was calculated according to the quantitative insulin-sensitivity check index (QUICKI). Results: SBP and DBP (both p < 0.001) and waist circumference (p = 0.02) were higher, and QUICKI (p = 0.043) and FMD (p = 0.01) were lower in the hypertensive group at baseline. After 3 months, nearly all the study parameters improved in both treatment groups. The decrease in BP, increase in FMD, and improvements in metabolic and anthropometric parameters were significantly greater in the moxonidine-treated group than in those treated with diet alone. Conclusion: Moxonidine is proposed as a valuable option for treating mild-to-moderate hypertension in obese and insulin-resistant patients with metabolic syndrome as it appears to improve endothelial dysfunction in these patients. © 2006 Adis Data Information BV. All rights reserved.
Açıklama
Anahtar Kelimeler
aminotransferase, cholesterol, gamma glutamyltransferase, glucose, insulin, moxonidine, triacylglycerol, adult, aminotransferase blood level, anthropometry, article, body mass, caloric restriction, cholesterol blood level, controlled study, drug effect, female, gamma glutamyl transferase blood level, glucose blood level, homeostasis, human, hypertension, insulin blood level, insulin resistance, insulin sensitivity, low calory diet, major clinical study, male, metabolic syndrome X, priority journal, triacylglycerol blood level, vascular endothelium, vasodilatation, waist circumference, waist hip ratio, Adult, Antihypertensive Agents, Blood Pressure Determination, Caloric Restriction, Combined Modality Therapy, Endothelium, Vascular, Female, gamma-Glutamyltransferase, Humans, Hypertension, Imidazoles, Male, Metabolic Syndrome X, Middle Aged, Obesity, Time Factors, Treatment Outcome, Waist-Hip Ratio
Kaynak
American Journal of Cardiovascular Drugs
WoS Q Değeri
Scopus Q Değeri
Q2
Cilt
6
Sayı
5
